



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
						<b>AMG-Studien</b>				
Mamma-Ca	x				<b>GeparDouze</b> EudraCT Number 2017-002771-25	A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with <b>Atezolizumab</b> or <b>Placebo</b> in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of <b>Atezolizumab</b> or <b>Placebo</b>				x
Mamma-Ca	x				<b>Keyriched</b> EudaCT Number 2018-003996-37	A prospective, multicenter, open label neoadjuvant phase II single arm study with <b>pembrolizumab</b> in combination with dual anti-HER2 blockade with <b>trastuzumab</b> and <b>pertuzumab</b> in early breast cancer patients with molecular HER2-enriched intrinsic subtype		x	x	
Mamma-Ca	x	x			<b>ADAPTcycle</b> EudraCT Number 2018-003749-40	Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus <b>ribociclib</b> versus chemotherapy in intermediate risk, HR+/HER2- early breast cancer (ADAPTcycle)	x			
Mamma-Ca		x			<b>SASCIA</b> EudaCT Number 2019-004100-35	Phase III postneoadjuvant study evaluating <b>Sacituzumab Govitecan</b> , an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA	x			x
Mamma-Ca			x		<b>NATALEE</b> EudaCT Number 2018-002998-21	A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of <b>ribociclib</b> with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).	x			
Mamma-Ca				x	<b>CBYL719H12301</b> <b>EPIK-B3</b> EudraCT Number 2019-002637-11	EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of <b>alpelisib (BYL719)</b> in combination with <b>nab-paclitaxel</b> in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation				x
Mamma-Ca				x	<b>CAPItello-291</b> EudraCT Number 2019-003629-78	A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of <b>Capivasertib + Fulvestrant</b> Versus <b>Placebo + Fulvestrant</b> as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) Protocol Number: D3615C00001	x			



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
------------	--------------	----------	-----------	----------	-----------	---------------------	-----------	----------	-----------	------

	Primär	Metastasiert								
Ovar-Ca		x	<b>AGO-OVAR 2.29</b> EutraCT Number 2017-000202-37	<b>Atezolizumab</b> in Kombination mit <b>Bevacizumab</b> und <b>Che-motherapie</b> versus Bevacizumab und Chemotherapie in re-zidivierendem Ovarialkarzinom – eine randomisierte Phase III Studie						

<b>Sonstige Studien</b>										
Mamma-Ca					<b>GATTUM</b>	Prospektive Evaluation der Notwendigkeit einer <b>atemgetriggerten Bestrahlung</b> (gating) beim linksseitigen Mammakarzinom	x	x	x	x
Mamma-Ca					<b>SaveHeart</b>	Prospektive Studie zur Herzschonung durch Bestrahlung in tiefer Inspiration bei linksseitigem Mammakarzinom	x	x	x	x
Mamma- Ca und Schwangerschaft					<b>GBG 29 (German Breast Group)</b>	Prospektive Registerstudie zur Diagnostik und Therapie des Mamma-karzinoms in der Schwangerschaft Pat. mit histologisch gesichertem Mammakarzinom und Schwangerschaft	x	x	x	x
Mamma-Ca				x	<b>GBG79 BrainMet</b>	Brain Metastases in Breast Cancer Network Germany (BMBC) Meeting a clinical need for the improvement of patient outcome	x	x	x	x
Mamma-Ca beim Mann					<b>Register Magdeburg</b>	Mammakarzinom des Mannes. Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit den klinischen Krebsregistern zur Diagnostik und Therapie des Mammakarzinoms des Mannes	x	x	x	x
Mamma-Ca					<b>P4-Studie TH-2018_01</b>	Prospective trial to predict the efficacy of platinum-based neo-adjuvant chemotherapy in BRCAness and PITX2 status in triple-negative breast cancer patients (P4-Studie)				x



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
------------	--------------	----------	-----------	----------	-----------	---------------------	-----------	----------	-----------	------

alle gyn. Tumorpatienten					<b>Psychonkologische Studie von ONKOTRAKT</b>	Epidemiologische Untersuchung zur Belastung von Krebspatienten (Verbesserung der Erkennung des psychoonkologischen Betreuungsbedarfs bei Krebskranken)				
Gyn-Sarkome	x	x	x	x	<b>REGSA</b>	Deutsche prospektive <b>Registerstudie</b> zur Erfassung der				
Endometrium-Ca					<b>PORTEC-4a</b>	Randomised Phase III Trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy for women with early stage endometrial cancer An international InterGroup trial				
Cervical-Ca					<b>FERTISS</b>	FERTility Sparing Surgery in cervical cancer patients outside controlled trials (FERTISS)				